Cargando…

PMEPA1/TMEPAI Is a Unique Tumorigenic Activator of AKT Promoting Proteasomal Degradation of PHLPP1 in Triple-Negative Breast Cancer Cells

SIMPLE SUMMARY: TMEPAI/PMEPA1 is known to be highly expressed in various types of cancer, including triple-negative breast cancer (TNBC). Here, we found that TMEPAI-knockout (KO) in TNBC cells showed less tumorigenic abilities and upregulated PHLPP1, which dephosphorylates AKT at Ser473. Additionall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haque, Md. Anwarul, Abdelaziz, Mohammed, Puteri, Meidi Utami, Vo Nguyen, Thanh Thao, Kudo, Kosei, Watanabe, Yukihide, Kato, Mitsuyasu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508116/ https://www.ncbi.nlm.nih.gov/pubmed/34638419 http://dx.doi.org/10.3390/cancers13194934

Ejemplares similares

TMEPAI/PMEPA1 enhances tumorigenic activities in lung cancer cells
por: Vo Nguyen, Thanh Thao, et al.
Publicado: (2014)

TGF-β-Induced TMEPAI Attenuates the Response of Triple-Negative Breast Cancer Cells to Doxorubicin and Paclitaxel
por: Wardhani, Bantari WK, et al.
Publicado: (2020)

TMEPAI/PMEPA1 Is a Positive Regulator of Skeletal Muscle Mass
por: Hagg, Adam, et al.
Publicado: (2020)

PCSK9 Promotes Cardiovascular Diseases: Recent Evidence about Its Association with Platelet Activation-Induced Myocardial Infarction
por: Puteri, Meidi Utami, et al.
Publicado: (2022)

Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-β from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer
por: Singha, Prajjal K., et al.
Publicado: (2019)

TGF-β induced TMEPAI/PMEPA1 inhibits canonical Smad signaling through R-Smad sequestration and promotes non-canonical PI3K/Akt signaling by reducing PTEN in triple negative breast cancer
por: Singha, Prajjal K., et al.
Publicado: (2014)

TGF-β-Induced TMEPAI Promotes Epithelial–Mesenchymal Transition in Doxorubicin-Treated Triple-Negative Breast Cancer Cells via SMAD3 and PI3K/AKT Pathway Alteration
por: Wardhani, Bantari W K, et al.
Publicado: (2021)

Ubiquitination and dynactin regulate TMEPAI lysosomal trafficking
por: Luo, Shenheng, et al.
Publicado: (2017)

Silencing of TRIM11 suppresses the tumorigenicity of chordoma cells through improving the activity of PHLPP1/AKT
por: Wang, Bin, et al.
Publicado: (2019)

Retraction Note: Silencing of TRIM11 suppresses the tumorigenicity of chordoma cells through improving the activity of PHLPP1/AKT
por: Wang, Bin, et al.
Publicado: (2023)

Detection of PHLPP1α/β in Human and Mouse Brain by Different Anti-PHLPP1 Antibodies
por: Jackson, Travis C., et al.
Publicado: (2015)

Recent Update on PCSK9 and Platelet Activation Experimental Research Methods: In Vitro and In Vivo Studies
por: Puteri, Meidi Utami, et al.
Publicado: (2022)

Methylation of the PMEPA1 gene, a negative regulator of the androgen receptor in prostate cancer
por: Sharad, Shashwat, et al.
Publicado: (2014)

PMEPA1 guards against TGF-β-mediated prostate cancer bone metastasis
por: Blee, Alexandra M., et al.
Publicado: (2016)

PMEPA1 Gene Isoforms: A Potential Biomarker and Therapeutic Target in Prostate Cancer
por: Sharad, Shashwat, et al.
Publicado: (2020)

PMEPA1 Serves as a Prognostic Biomarker and Correlates with Immune Infiltrates in Cervical Cancer
por: Li, Jing, et al.
Publicado: (2022)

SUN-140 TMEPAI Inhibits SMAD 2/3 Mediated Muscle Wasting
por: Kharoud, Swati, et al.
Publicado: (2020)

PHLPP1 is a metastasis suppressor in melanoma
por: Dai, Meng, et al.
Publicado: (2018)

Aberrant Expression of PHLPP1 and PHLPP2 Correlates with Poor Prognosis in Patients with Hypopharyngeal Squamous Cell Carcinoma
por: Zhou, Jieyu, et al.
Publicado: (2015)

PMEPA1 Is a Prognostic Biomarker That Correlates With Cell Malignancy and the Tumor Microenvironment in Bladder Cancer
por: Qiu, Dongxu, et al.
Publicado: (2021)

High level expression of STAG1/PMEPA1 in an androgen-independent prostate cancer PC3 subclone
por: Hirokawa, Yoshifumi S., et al.
Publicado: (2007)

Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients
por: Amalia, Muttia, et al.
Publicado: (2023)

Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN
por: Li, Hua, et al.
Publicado: (2015)

PMEPA1 induces EMT via a non‐canonical TGF‐β signalling in colorectal cancer
por: Zhang, Lei, et al.
Publicado: (2019)

Cutting the brakes and flooring the gas: how TMEPAI turns TGF-β into a tumor promoter
por: Cichon, Magdalena A., et al.
Publicado: (2014)

PMEPA1 isoform a drives progression of glioblastoma by promoting protein degradation of the Hippo pathway kinase LATS1
por: Ji, Jianxiong, et al.
Publicado: (2019)

PHLPP1 counter-regulates STAT1-mediated inflammatory signaling
por: Cohen Katsenelson, Ksenya, et al.
Publicado: (2019)

Transcription factor SNAI2 exerts pro-tumorigenic effects on glioma stem cells via PHLPP2-mediated Akt pathway
por: Peng, Lilei, et al.
Publicado: (2022)

Emerging roles of PHLPP phosphatases in metabolism
por: Cha, Jong-Ho, et al.
Publicado: (2021)

Chondrocytic and pharmacokinetic properties of Phlpp inhibitors
por: Taylor, E.L., et al.
Publicado: (2021)

The “ NF-ĸ B interacting long noncoding RNA” ( NKILA) transcript is antisense to cancer-associated gene PMEPA1
por: Dijkstra, Johannes M., et al.
Publicado: (2015)

Evolutionary analysis of PHLPP1 gene in humans and non-human primates
por: Anbazhagan, Padmanabhan, et al.
Publicado: (2008)

PHLPP1 regulates CFTR activity and lumen expansion through AMPK
por: Lobert, Viola H., et al.
Publicado: (2022)

Brazilin from Caesalpinia sappan L. as a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor: Pharmacophore-Based Virtual Screening, In Silico Molecular Docking, and In Vitro Studies
por: Iqbal, Muhammad, et al.
Publicado: (2023)

Hdac3 deletion in myeloid progenitor cells enhances bone healing in females and limits osteoclast fusion via Pmepa1
por: Molstad, David H. H., et al.
Publicado: (2020)

Emerging roles of PHLPP phosphatases in lung cancer
por: Xia, Xinhang, et al.
Publicado: (2023)

Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL)
por: O'Hayre, M, et al.
Publicado: (2012)

Inhibition of PHLPP1/2 phosphatases rescues pancreatic β-cells in diabetes
por: Lupse, Blaz, et al.
Publicado: (2021)

PHLPP1 deficiency protects against age‐related intervertebral disc degeneration
por: Zhang, Changli, et al.
Publicado: (2022)

PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma
por: Molina, Jennifer R., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kjhj0ujkghsouqcrtlnl80qdfa